Atazanavir 200 MG Oral Capsule — RxCUI 402247
RxNorm drug concept · Semantic clinical drug
RxCUI 402247
Semantic clinical drug · SCD
● Current RxNorm concept 16 FDA products
36 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI402247
Official nameAtazanavir 200 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asatazanavir 200 MG (as atazanavir sulfate 227.8 MG) Oral Capsule; atazanavir sulfate 200 MG Oral Capsule
FDA products mapped16
Package NDCs mapped36
Reported Medicaid activity (SDUD)980 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Atazanavir: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- This is one of the most common things people notice on atazanavir, and it happens to almost everyone who takes it. The medicine causes a buildup of a pigment called bilirubin in yo...
- Why does my skin and the whites of my eyes look yellow since I started atazanavir?
- Yes — this one really matters. Taking atazanavir with food can increase the amount your body absorbs by a significant margin, and it also keeps your blood levels more consistent th...
- Do I really have to take this with food every single time?
🕸️ Concept Web — How Atazanavir 200 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Atazanavir 200 MG Oral Capsule
RxCUI 402247 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Atazanavir
343047IN
-
Atazanavir
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Reyataz
382467BN
-
Reyataz
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Atazanavir Oral Capsule
402370SCDF -
Atazanavir Oral Product
1154364SCDG -
Atazanavir Pill
1154365SCDG -
Atazanavir Oral Capsule [Reyataz]
402333SBDF -
Reyataz Oral Product
1183050SBDG -
Reyataz Pill
1183051SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Atazanavir Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Atazanavir 200 MG
402332SCDC -
Atazanavir 200 MG Oral Capsule [Reyataz]
402093SBD -
Atazanavir 200 MG [Reyataz]
576101SBDC
-
Atazanavir 200 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Atazanavir 200 MG
SCDC · 402332 -
Atazanavir Oral Capsule
SCDF · 402370 -
Atazanavir Oral Product
SCDG · 1154364 -
Atazanavir Pill
SCDG · 1154365
Brand-Name Concepts
-
Atazanavir 200 MG Oral Capsule [Reyataz]
SBD · 402093 -
Atazanavir 200 MG [Reyataz]
SBDC · 576101 -
Atazanavir Oral Capsule [Reyataz]
SBDF · 402333 -
Reyataz Oral Product
SBDG · 1183050 -
Reyataz Pill
SBDG · 1183051 -
Reyataz
BN · 382467
📦 FDA Products & Package NDCs
16 products · 36 package NDCs
36 package NDCs map to RxCUI 402247 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00003-3622-12 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3622-1... | REYATAZ | E.R. Squibb & Sons, L.L.C. | 2003-06-24 |
| 00003-3631-12 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE, PLASTIC (0003-3631-1... | REYATAZ | E.R. Squibb & Sons, L.L.C. | 2003-06-24 |
| 00003-3638-10 | 30 PACKET in 1 CARTON (0003-3638-10) / 1 POWDER in 1 PACKET | REYATAZ | E.R. Squibb & Sons, L.L.C. | 2014-12-19 |
| 00093-5526-06 | 60 CAPSULE in 1 BOTTLE (0093-5526-06) | Atazanavir Sulfate | Teva Pharmaceuticals USA, Inc. | 2017-12-27 |
| 00093-5527-06 | 60 CAPSULE in 1 BOTTLE (0093-5527-06) | Atazanavir Sulfate | Teva Pharmaceuticals USA, Inc. | 2017-12-27 |
| 00093-5528-56 | 30 CAPSULE in 1 BOTTLE (0093-5528-56) | Atazanavir Sulfate | Teva Pharmaceuticals USA, Inc. | 2017-12-27 |
| 31722-0653-10 | 1000 CAPSULE in 1 BOTTLE (31722-653-10) | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0653-31 | 100 BLISTER PACK in 1 CARTON (31722-653-31) / 10 CAPSULE in... | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0653-60 | 60 CAPSULE in 1 BOTTLE (31722-653-60) | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0654-10 | 1000 CAPSULE in 1 BOTTLE (31722-654-10) | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0654-31 | 100 BLISTER PACK in 1 CARTON (31722-654-31) / 10 CAPSULE in... | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0654-60 | 60 CAPSULE in 1 BOTTLE (31722-654-60) | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0655-05 | 500 CAPSULE in 1 BOTTLE (31722-655-05) | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0655-30 | 30 CAPSULE in 1 BOTTLE (31722-655-30) | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 31722-0655-31 | 100 BLISTER PACK in 1 CARTON (31722-655-31) / 10 CAPSULE in... | Atazanavir | Camber Pharmaceuticals, Inc. | 2022-02-07 |
| 42385-0920-48 | 10 BLISTER PACK in 1 CARTON (42385-920-48) / 6 CAPSULE in 1... | Atazanavir | Laurus Labs Limited | 2021-04-30 |
| 42385-0920-60 | 60 CAPSULE in 1 BOTTLE (42385-920-60) | Atazanavir | Laurus Labs Limited | 2021-04-30 |
| 42385-0921-48 | 10 BLISTER PACK in 1 CARTON (42385-921-48) / 6 CAPSULE in 1... | Atazanavir | Laurus Labs Limited | 2021-04-30 |
| 42385-0921-60 | 60 CAPSULE in 1 BOTTLE (42385-921-60) | Atazanavir | Laurus Labs Limited | 2021-04-30 |
| 42385-0922-30 | 30 CAPSULE in 1 BOTTLE (42385-922-30) | Atazanavir | Laurus Labs Limited | 2021-04-30 |
| 42385-0922-37 | 5 BLISTER PACK in 1 CARTON (42385-922-37) / 6 CAPSULE in 1... | Atazanavir | Laurus Labs Limited | 2021-04-30 |
| 65862-0710-03 | 3 BLISTER PACK in 1 CARTON (65862-710-03) / 10 CAPSULE in 1... | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0710-05 | 500 CAPSULE in 1 BOTTLE (65862-710-05) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0710-60 | 60 CAPSULE in 1 BOTTLE (65862-710-60) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0711-03 | 3 BLISTER PACK in 1 CARTON (65862-711-03) / 10 CAPSULE in 1... | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0711-05 | 500 CAPSULE in 1 BOTTLE (65862-711-05) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0711-18 | 180 CAPSULE in 1 BOTTLE (65862-711-18) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0711-60 | 60 CAPSULE in 1 BOTTLE (65862-711-60) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0712-03 | 3 BLISTER PACK in 1 CARTON (65862-712-03) / 10 CAPSULE in 1... | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0712-05 | 500 CAPSULE in 1 BOTTLE (65862-712-05) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0712-18 | 180 CAPSULE in 1 BOTTLE (65862-712-18) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0712-60 | 60 CAPSULE in 1 BOTTLE (65862-712-60) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0713-03 | 3 BLISTER PACK in 1 CARTON (65862-713-03) / 10 CAPSULE in 1... | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0713-05 | 500 CAPSULE in 1 BOTTLE (65862-713-05) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0713-30 | 30 CAPSULE in 1 BOTTLE (65862-713-30) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
| 65862-0713-90 | 90 CAPSULE in 1 BOTTLE (65862-713-90) | Atazanavir Sulfate | Aurobindo Pharma Limited | 2018-06-25 |
Observed labelers:
Aurobindo Pharma Limited (15) ·
Camber Pharmaceuticals, Inc. (9) ·
Laurus Labs Limited (6) ·
E.R. Squibb & Sons, L.L.C. (3) ·
Teva Pharmaceuticals USA, Inc. (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.